Rabbit Recombinant Monoclonal IP10 antibody. Suitable for I-ELISA, WB and reacts with Recombinant fragment - Human, Human samples. Cited in 2 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
I-ELISA | WB | |
---|---|---|
Human | Expected | Tested |
Recombinant fragment - Human | Tested | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - Human | Dilution info - | Notes - |
Select an associated product type
Pro-inflammatory cytokine that is involved in a wide variety of processes such as chemotaxis, differentiation, and activation of peripheral immune cells, regulation of cell growth, apoptosis and modulation of angiostatic effects (PubMed:11157474, PubMed:22652417, PubMed:7540647). Plays thereby an important role during viral infections by stimulating the activation and migration of immune cells to the infected sites (By similarity). Mechanistically, binding of CXCL10 to the CXCR3 receptor activates G protein-mediated signaling and results in downstream activation of phospholipase C-dependent pathway, an increase in intracellular calcium production and actin reorganization (PubMed:12750173, PubMed:19151743). In turn, recruitment of activated Th1 lymphocytes occurs at sites of inflammation (PubMed:12663757, PubMed:12750173). Activation of the CXCL10/CXCR3 axis also plays an important role in neurons in response to brain injury for activating microglia, the resident macrophage population of the central nervous system, and directing them to the lesion site. This recruitment is an essential element for neuronal reorganization (By similarity).
INP10, SCYB10, CXCL10, C-X-C motif chemokine 10, 10 kDa interferon gamma-induced protein, Small-inducible cytokine B10, Gamma-IP10, IP-10
Rabbit Recombinant Monoclonal IP10 antibody. Suitable for I-ELISA, WB and reacts with Recombinant fragment - Human, Human samples. Cited in 2 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
IP10 also known as CXCL10 is a small cytokine belonging to the CXC chemokine family. It has a molecular mass of approximately 8.7 kDa. IP10 is secreted by several cell types such as monocytes endothelial cells and fibroblasts in response to interferon-gamma (IFN-γ). This protein is involved in immune responses and exhibits various roles especially in chemoattracting cells. Researchers often measure IP10 concentrations using ELISA kits such as the IP-10 ELISA to study its expression levels in different biological contexts.
IP10 plays a role in modulating the activities of immune cells. It attracts T cells eosinophils monocytes and natural killer (NK) cells by binding to the CXCR3 receptor. IP10 is not part of a larger complex but interacts with other cytokines to influence cell migration and the immune response. High levels of IP10 can reflect strong immune activation which is why it is often measured in inflammatory conditions using standard assays like the IP-10 ELISA kits.
The role of IP10 lies within the Th1-type immune response pathway. In this pathway IP10 works alongside other chemokines to recruit and activate immune cells to sites of inflammation or infection. It synergizes with IFN-γ to propagate immune signals. IP10 is also linked with the CXCR3 receptor which plays a critical role in these pathways providing a connection to other proteins such as CXCL9 and CXCL11 which have similar functions in cell-mediated immunity.
IP10 is associated with conditions like multiple sclerosis and rheumatoid arthritis. Elevated IP10 levels often correlate with disease activity in these disorders making it a potential biomarker for disease progression. The protein interacts with other inflammatory mediators such as TNF-α in regulating immune activity within these disease contexts. IP10's involvement in recruiting immune cells contributes to the pathogenic inflammation observed in these conditions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
ab214668 was shown to react with IP10 in wild-type A549 cells in western blot with loss of signal observed in IP10 knockout cell line Human CXCL10 (IP10) knockout A549 cell line ab266971 (knockout cell lysate Human CXCL10 (IP10) knockout A549 cell lysate ab256888). Wild-type and IP10 knockout A549 cell lysates were subjected to SDS-PAGE. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with ab214668 and Anti-GAPDH antibody [6C5] - Loading Control ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-IP10 antibody [EPR20764] (ab214668) at 1/1000 dilution
Lane 1: Wild-type A549 Brefeldin A (Brefeldin A, Inhibitor of ADP-ribosylation factor ab120299)-treated (5ug/ml, 6h) cell lysate at 30 µg
Lane 2: Wild-type A549 IFN-y (Recombinant Human Interferon gamma protein (Active) ab259377) (100 ng/ml, 32 h) and TNF-alpha (Recombinant human TNF alpha protein (Active) ab259410) (10 ng/ml, 32h), and Brefeldin A (Brefeldin A, Inhibitor of ADP-ribosylation factor ab120299)-treated (5ug/ml for the last 6h) cell lysate at 30 µg
Lane 2: Western blot - Human CXCL10 (IP10) knockout A549 cell line (Human CXCL10 (IP10) knockout A549 cell line ab266971)
Lane 3: IP10 knockout A549 Brefeldin A (Brefeldin A, Inhibitor of ADP-ribosylation factor ab120299)-treated (5ug/ml, 6h) cell lysate at 30 µg
Lane 4: IP10 knockout A549 IFN-y (Recombinant Human Interferon gamma protein (Active) ab259377) (100ng/ml, 32h) and TNF-alpha (Recombinant human TNF alpha protein (Active) ab259410) (10ng/ml, 32h), and Brefeldin A (Brefeldin A, Inhibitor of ADP-ribosylation factor ab120299)-treated (5ug/ml for the last 6h) cell lysate at 30 µg
Lane 5: THP-1 Brefeldin A (Brefeldin A, Inhibitor of ADP-ribosylation factor ab120299)-treated (5ug/ml, 6h) cell lysate at 30 µg
Lane 6: THP-1 IFN-y (Recombinant Human Interferon gamma protein (Active) ab259377) (200ng/ml, 24h) and LPS (50ng/ml, 24h)-treated for 24 hours, and Brefeldin A (Brefeldin A, Inhibitor of ADP-ribosylation factor ab120299)-treated (5ug/ml for the last 6h) cell lysate at 30 µg
Performed under reducing conditions.
Predicted band size: 10 kDa
Observed band size: 11 kDa
False colour image of Western blot: Anti-IP10 antibody [EPR20764] staining at 1/1000 dilution, shown in green; Mouse anti-Alpha Tubulin [DM1A] (Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab214668 was shown to bind specifically to IP10. A band was observed at 11 kDa in treated wild-type THP-1 cell lysates with no signal observed at this size in treated CXCL10 knockout cell line Human CXCL10 (IP10) knockout THP-1 cell line ab277860 (knockout cell lysate ab283141). To generate this image, wild-type and CXCL10 knockout THP-1 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.
All lanes: Western blot - Anti-IP10 antibody [EPR20764] (ab214668) at 1/1000 dilution
Lane 1: Wild-type THP-1 vehicle control IFNg (0 ng/ml, 32 h), TNF-alpha (0 ng/ml, 32 h), Brefeldin A (5 ug/ml, 6 h) cell lysate at 20 µg
Lane 2: Wild-type THP-1 treated IFNg (100 ng/ml, 32 h), TNF-alpha (10 ng/ml, 32 h), Brefeldin A (5 ug/ml, 6 h) cell lysate at 20 µg
Lane 3: CXCL10 knockout THP-1 vehicle control IFNg (0 ng/ml, 32 h), TNF-alpha (0 ng/ml, 32 h), Brefeldin A (5 ug/ml, 6 h) cell lysate at 20 µg
Lane 4: CXCL10 knockout THP-1 treated IFN-gamma (100 ng/ml, 32 h), TNF-alpha (10 ng/ml, 32 h), Brefeldin A (5 ug/ml, 6 h) cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 10 kDa
Observed band size: 11 kDa
False colour image of Western blot: Anti-IP10 antibody [EPR20764] staining at 1/1000 dilution, shown in green; Mouse anti-Alpha Tubulin [DM1A] (Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab214668 was shown to bind specifically to IP10. A band was observed at 11 kDa in wild-type A549 cell lysates with no signal observed at this size in CXCL10 knockout cell line Human CXCL10 (IP10) knockout A549 cell line ab266970 (knockout cell lysate ab256887). To generate this image, wild-type and CXCL10 knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.
All lanes: Western blot - Anti-IP10 antibody [EPR20764] (ab214668) at 1/1000 dilution
Lane 1: Wild-type A549 Vehicle Control IFN-gamma (0 ng/mL, 32 h) + TNF-alpha (0 ng/mL, 32h) + BFA (0 u/mL, 6h) cell lysate at 20 µg
Lane 2: Wild-type A549 Treated IFN-gamma (100 ng/mL, 32 h) + TNF-alpha (10 ng/mL, 32h) + BFA (5 u/mL, 6h) cell lysate at 20 µg
Lane 3: CXCL10 knockout A549 Vehicle Control IFN-gamma (0 ng/mL, 32 h) + TNF-alpha (0 ng/mL, 32h) + BFA (0 u/mL, 6h) cell lysate at 20 µg
Lane 4: CXCL10 knockout A549 Treated IFN-gamma (100 ng/mL, 32 h) + TNF-alpha (10 ng/mL, 32h) + BFA (5 u/mL, 6h) cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 10 kDa
Observed band size: 11 kDa
IP10 protein secretion can be induced by IFN-gamma treatment (PMID: 11907072).
All lanes: Western blot - Anti-IP10 antibody [EPR20764] (ab214668) at 1/1000 dilution
Lane 1: Untreated THP-1 (human monocytic leukemia cell line) culture supernatant at 15 µL
Lane 2: THP-1 treated with 200 ng/ml interferon-gamma (IFN-gamma, Recombinant human Interferon gamma protein (Active) ab9659) and 50 ng/ml lipopolysaccharides (LPS) for 24 hours, culture supernatant at 15 µL
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Developed using the ECL technique.
Predicted band size: 10 kDa
Observed band size: 12 kDa
Exposure time: 15s
ab214668 was shown to react with IP10 in wild-type A549 cells in western blot with loss of signal observed in IP10 knockout cell line Human CXCL10 (IP10) knockout A549 cell line ab266971 (knockout cell lysate Human CXCL10 (IP10) knockout A549 cell lysate ab256888). Wild-type and IP10 knockout A549 cell lysates were subjected to SDS-PAGE. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with ab214668 and Anti-GAPDH antibody [6C5] - Loading Control ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-IP10 antibody [EPR20764] (ab214668) at 1/1000 dilution
Lane 1: Wild-type A549 Brefeldin A (Brefeldin A, Inhibitor of ADP-ribosylation factor ab120299)-treated (5ug/ml, 6h) cell lysate at 30 µg
Lane 2: Wild-type A549 IFN-y (Recombinant Human Interferon gamma protein (Active) ab259377) (100 ng/ml, 32 h) and TNF-alpha (Recombinant human TNF alpha protein (Active) ab259410) (10 ng/ml, 32h), and Brefeldin A (Brefeldin A, Inhibitor of ADP-ribosylation factor ab120299)-treated (5ug/ml for the last 6h) cell lysate at 30 µg
Lane 2: Western blot - Human CXCL10 (IP10) knockout THP-1 cell line (Human CXCL10 (IP10) knockout THP-1 cell line ab277860)
Lane 3: IP10 knockout A549 Brefeldin A (Brefeldin A, Inhibitor of ADP-ribosylation factor ab120299)-treated (5ug/ml, 6h) cell lysate at 30 µg
Lane 4: IP10 knockout A549 IFN-y (Recombinant Human Interferon gamma protein (Active) ab259377) (100ng/ml, 32h) and TNF-alpha (Recombinant human TNF alpha protein (Active) ab259410) (10ng/ml, 32h), and Brefeldin A (Brefeldin A, Inhibitor of ADP-ribosylation factor ab120299)-treated (5ug/ml for the last 6h) cell lysate at 30 µg
Lane 5: THP-1 Brefeldin A (Brefeldin A, Inhibitor of ADP-ribosylation factor ab120299)-treated (5ug/ml, 6h) cell lysate at 30 µg
Lane 6: THP-1 IFN-y (Recombinant Human Interferon gamma protein (Active) ab259377) (200ng/ml, 24h) and LPS (50ng/ml, 24h)-treated for 24 hours, and Brefeldin A (Brefeldin A, Inhibitor of ADP-ribosylation factor ab120299)-treated (5ug/ml for the last 6h) cell lysate at 30 µg
Performed under reducing conditions.
Predicted band size: 10 kDa
ELISA analysis of CXCL10 recombinant protein at 1000 ng/mL with ab214668. An Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) at 1/2500 dilution was used as the secondary antibody.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com